



# CLCZ696B2319E1 Open Label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With Heart Failure (HF).

22/11/2024 11:04:09

## Main Information

**Primary registry identifying number**

LBCTR2019070266

**Protocol number**

CLCZ696B2319E1

**MOH registration number**

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

**Primary sponsor**

Novartis Pharma Services

**Primary sponsor: Country of origin**

Novartis Pharmaceuticals

**Date of registration in primary registry**

29/05/2021

**Date of registration in national regulatory agency**

**Public title**

CLCZ696B2319E1 Open Label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With Heart Failure (HF).

**Acronym**

**Scientific title**

A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319

**Acronym**

**Brief summary of the study: English**

The purpose of this study is to evaluate long-term safety and tolerability data in eligible CLCZ696B2319 (PANORAMA-HF) patients receiving open-label sacubitril/valsartan

**Brief summary of the study: Arabic**

دراسة متعددة المراكز لتقييم السلامة الطويلة الأمد لدواء ساكوبيتريل / فالسارتان المفتوح اللصاقة وقدرة تحمله لدى أطفال مرضى مصابين بفشل القلب بسبب الخلل الوظيفي الانقباضي الجهازى للبطين الأيسر وقد أنجزوا دراسة CLCZ696B2319

**Health conditions/problem studied: Specify**

Heart failure patients

**Interventions: Specify**

Drug: sacubitril/valsartan

Target dose 3.1 mg/kg bid





**Formulations:**

Tablets (50, 100, 200 mg) Granules [12.5 mg (4 granules), 31.25 mg (10 granules), in capsules] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)

Other Name: LCZ696

**Key inclusion and exclusion criteria: Inclusion criteria**

Signed informed consent  
On study drug at PANORAMA-HF Part 2 End of Study visit. Does not have any significant safety issue

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender**

**Key inclusion and exclusion criteria: Age minimum**

1

**Key inclusion and exclusion criteria: Age maximum**

18

**Key inclusion and exclusion criteria: Exclusion criteria**

Subject only participated in PANORAMA-HF Part 1 or was a Screen Failure in PANORAMA-HF or permanently discontinued study drug in PANORAMA-HF Part 2  
Use of investigational drugs within 5 half-lives of enrollment or within 30 days (longer duration); with the exception of PANORAMA-HF study drug (requires  $\geq 36$ -hour washout before baseline visit)  
History of hypersensitivity or allergy to study treatment, its excipients or drugs of similar chemical class, ACEIs, ARBs, or NEP inhibitor and known/suspected contraindications to sacubitril/valsartan  
Renal vascular hypertension (including renal artery stenosis)  
Significant renal estimated glomerular filtration rate disorder (eGFR calculated using modified Schwartz formula  $< 30\%$  mean GFR for age); hepatic disorder (serum aspartate aminotransferase or alanine aminotransferase  $> 3$  times upper limit of normal); gastrointestinal disorder or biliary disorder  
History of angioedema  
Parents or legal guardians of subject who do not give consent or allow the child to give assent, or inability of patient or parents/legal guardians to follow instructions or comply with follow-up procedures  
Any medical condition(s) that may put the patient at risk in the investigator's opinion or that the investigator deems unsuitable for the study  
Other protocol defined inclusion/exclusion criteria may apply

**Type of study**

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

N/A

**Trial scope**

Safety

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

N/A: Single arm study

**Study design: Masking**

Open (masking not used)

**Study design: Control**

N/A

**Study phase**

2

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Single

**Study design: Specify assignment**

N/A

**IMP has market authorization**

Yes, Lebanon and Worldwide

**IMP has market authorization: Specify**

Lebanon and worldwide : yes for the dosage forms 50,100 and 200 mg and No for 12.5 and 31.25 mg

**Name of IMP**

sacubitril/valsartan

**Year of authorization**

2015

**Month of authorization**

11

**Type of IMP**

Others

**Pharmaceutical class**

LCZ696, also known as Entresto® (sacubitril/valsartan) is an angiotensin receptor neprilysin inhibitor (ARNI), providing concomitant neprilysin (neutral endopeptidase 24.11, NEP) inhibition and angiotensin II type 1 (AT1) receptor blockade

**Therapeutic indication**

Pediatric patients with heart failure

**Therapeutic benefit**

long-term safety and tolerability data in eligible CLCZ696B2319 (PANORAMA-HF) patients receiving open-label sacubitril/valsartan.

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration****Target follow-up duration: Unit****Number of groups/cohorts****Biospecimen retention**

Samples without DNA

**Biospecimen description**

blood and urine samples

**Target sample size**

10

**Actual enrollment target size**

1

**Date of first enrollment: Type**

Actual

**Date of first enrollment: Date**

03/01/2020

**Date of study closure: Type**

Actual

**Date of study closure: Date**

24/08/2022

**Recruitment status**

Recruiting

**Recruitment status: Specify****Date of completion**

21/04/2021

**IPD sharing statement plan**

No

**IPD sharing statement description**

Undecided

**Additional data URL**

<https://clinicaltrials.gov/ct2/show/record/NCT03785405?cond=pediatric+heart+failure&rank=8&view=record>

**Admin comments****Trial status**

Approved

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
Clinicaltrials.gov	NCT03785405

## Sources of Monetary or Material Support

Name
Novartis Pharma Services

## Secondary Sponsors

Name
NA

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Linda Daou	Beirut	Lebanon	961604976	drlindadaou@gmail.com	Hotel Dieu
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Ghassan Chehab	Beirut	Lebanon	9613388581	ghassanchehab@yahoo.com	Rafik Hariri UNiversity Hospital



## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hotel Dieu de France	Linda Daou	Pediatric Cardiology	Approved
Rafik Hariri University Hospital	Ghassan Chehab	Cardiology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	06/06/2019	Sami Richa	cue@usj.edu.lb	961421229
Rafic Hariri University Hospital	28/01/2019	Rawan Yamout	rawan.yamout@crurhuh.com	018300000 ext 2037

## Countries of Recruitment

Name
Austria
Argentina
Canada
Croatia
Czech Republic
Egypt
Finland
France
Germany
Hungary
India
Japan
Jordan
Poland





Portugal
Romania
Russian Federation
Saudi Arabia
Singapore
South Africa
Democratic People Republic of Korea
Spain
Sweden
Switzerland
Thailand
Turkey
United Kingdom
United States of America
Lebanon

## Health Conditions or Problems Studied

Condition	Code	Keyword
Heart Failure	Heart failure (I50)	HF

## Interventions

Intervention	Description	Keyword
ICF, Physical Exam, ECG, Lab tests	ICF, Physical Exam, ECG, Lab tests	ICF, Physical Exam, ECG, Lab tests



## Primary Outcomes

Name	Time Points	Measure
Number of participants with Adverse Events (AEs) as a measure of safety and tolerability	to end of study, up to 3 years	safety and tolerability
.Number of participants with Serious Adverse Events (SAEs) as a measure of safety and tolerability	to end of study, up to 3 years	safety and tolerability

## Key Secondary Outcomes

Name	Time Points	Measure
No secondary objectives	NA	NA

## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files